Comparable COVID‐19 outcomes with current use of GLP‐1 receptor agonists, DPP‐4 inhibitors or SGLT‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV‐2 DOI Open Access
Simone Bastrup Israelsen, Anton Pottegård, Håkon Sandholdt

et al.

Diabetes Obesity and Metabolism, Journal Year: 2021, Volume and Issue: 23(6), P. 1397 - 1401

Published: Jan. 27, 2021

Incretin-based therapies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been hypothesized to exert beneficial effects on COVID-19 outcomes due anti-inflammatory properties. In this population-based cohort study, we retrieved data from nationwide registries all individuals diagnosed with severe acute respiratory syndrome coronavirus 2 infection up 1 November 2020. For diabetes, examined the impact of use GLP-1 RAs (n = 370) DPP-4i 284) compared sodium-glucose cotransporter-2 (SGLT-2i) 342) risk hospital admission outcomes. Relative risks (RRs) were calculated after applying propensity score weighted methods control for confounding. Current users had an adjusted RR 0.89 (95% confidence interval 0.34-2.33), while 2.42 0.99-5.89) 30-day mortality SGLT-2i use. Further, or was not associated decreased admission. Thus, incretin-based therapies in diabetes (SARS-CoV-2) improved clinical

Language: Английский

COVID-19 and diabetes mellitus: from pathophysiology to clinical management DOI Creative Commons
Soo Lim, Jae Hyun Bae, Hyuk‐Sang Kwon

et al.

Nature Reviews Endocrinology, Journal Year: 2020, Volume and Issue: 17(1), P. 11 - 30

Published: Nov. 13, 2020

Language: Английский

Citations

939
Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection DOI Creative Commons
Laura Montefusco, Moufida Ben Nasr, Francesca D’Addio

et al.

Nature Metabolism, Journal Year: 2021, Volume and Issue: 3(6), P. 774 - 785

Published: May 25, 2021

Language: Английский

Citations

364
Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning DOI Creative Commons
Daniel J. Drucker

Cell Metabolism, Journal Year: 2021, Volume and Issue: 33(3), P. 479 - 498

Published: Jan. 22, 2021

Language: Английский

Citations

245
Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis DOI Creative Commons
Giovanni Corona, Alessandro Pizzocaro, Walter Vena

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2021, Volume and Issue: 22(2), P. 275 - 296

Published: Feb. 22, 2021

Language: Английский

Citations

218
COVID-19 and metabolic disease: mechanisms and clinical management DOI Creative Commons
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2021, Volume and Issue: 9(11), P. 786 - 798

Published: Oct. 6, 2021

Language: Английский

Citations

217
Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay DOI Creative Commons
Anoop Narayanan, M. Narwal, Sydney A. Majowicz

et al.

Communications Biology, Journal Year: 2022, Volume and Issue: 5(1)

Published: Feb. 25, 2022

Abstract SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug development. In this study, we present an screening strategy involving a novel in-cell protease assay, biochemical activity assessments, as well structural determinations rapid identification of inhibitors with low cytotoxicity. We identified eight compounds anti-SARS-CoV-2 from library 64 repurposed drugs modeled at active sites by in silico docking. demonstrate that Sitagliptin Daclatasvir inhibit PLpro, MG-101, Lycorine HCl, Nelfinavir mesylate SARS-CoV-2. The X-ray crystal structure complex MG-101 shows covalent bond formation between the inhibitor site Cys145 residue indicating its mechanism inhibition is blocking substrate binding site. Thus, provide methods effective development virus polyprotein processing antivirals. Additionally, show combined more inhibiting delta variant.

Language: Английский

Citations

183
COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course DOI Creative Commons
Cyril P. Landstra, Eelco J.P. de Koning

Frontiers in Endocrinology, Journal Year: 2021, Volume and Issue: 12

Published: June 17, 2021

The relationship between COVID-19 and diabetes mellitus is complicated bidirectional. On the one hand, considered of most important risk factors for a severe course COVID-19. Several that are often present in likely to contribute this risk, such as older age, proinflammatory hypercoagulable state, hyperglycemia underlying comorbidities (hypertension, cardiovascular disease, chronic kidney disease obesity). other infection, its treatment with steroids, can have specific negative impact on itself, leading worsening through increased insulin resistance reduced β-cell secretory function. Worsening can, turn, adversely affect Although more knowledge gradually surfaces pandemic progresses, challenges understanding interrelationship remain.

Language: Английский

Citations

180
Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England DOI Open Access
Kamlesh Khunti,

Peter Knighton,

Francesco Zaccardi

et al.

The Lancet Diabetes & Endocrinology, Journal Year: 2021, Volume and Issue: 9(5), P. 293 - 303

Published: March 31, 2021

Language: Английский

Citations

177
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications DOI Creative Commons
Andrey Santos, Daniéla Oliveira Magro, Rosana Evangelista Poderoso

et al.

Diabetology & Metabolic Syndrome, Journal Year: 2021, Volume and Issue: 13(1)

Published: March 1, 2021

Abstract Background Our understanding of the pathophysiology COVID-19 manifestations and evolution has improved over past 10 months, but reasons why is more severe in obese diabetic patients are not yet completely understood. Main text In present review we discuss different mechanisms that may contribute to explain including viral entrance, direct toxicity, endothelial dysfunction, thromboinflammation, dysregulation immune response, renin–angiotensin–aldosterone system. Conclusions We show infection activates an integrated stress activations serine kinases such as PKR PERK, which induce IRS-1 phosphorylation insulin resistance. parallel, correlate synergy resistance with this hormonal obesity diabetes, increase severity disease. Finally, potential beneficial effects drugs used treat diabetes COVID-19.

Language: Английский

Citations

122
Small molecules in the treatment of COVID-19 DOI Creative Commons
Sibei Lei, Xiaohua Chen, Jieping Wu

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Dec. 5, 2022

Abstract The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to societies economies. Until now, effective therapeutics against are in high demand. Along with our improved understanding the structure, function, pathogenic process SARS-CoV-2, many small molecules potential anti-COVID-19 effects have been developed. So far, several antiviral strategies were explored. Besides directly inhibition viral proteins such as RdRp M pro , interference host enzymes including ACE2 proteases, blocking relevant immunoregulatory pathways represented by JAK/STAT, BTK, NF-κB, NLRP3 pathways, regarded feasible drug development. development treat achieved strategies, computer-aided lead compound design screening, natural product discovery, repurposing, combination therapy. Several representative remdesivir paxlovid proved or authorized emergency use countries. And candidates entered clinical-trial stage. Nevertheless, due epidemiological features variability issues it is necessary continue exploring novel COVID-19. This review discusses current findings for treatment. Moreover, their detailed mechanism action, chemical structures, preclinical clinical efficacies discussed.

Language: Английский

Citations

85